Quest Diagnostics Inc. (DGX)
NYSE · Common stock · Services-Medical Laboratories
As of Oct 21, 2:18 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow DGX in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on DGX and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
DGX at a glance
Key statistics
$26.17B
Market capitalization
- Previous close
- $237.12
- Open
- $236.20
- Day range
- $232.32 – $239.41
- Volume
- 500.9K
- Average volume (30 sessions)
- 1.12M
- Shares outstanding
- 110.37M
- Price / earnings
- 24.7
- Earnings per share
- $9.59
- Price / book
- 3.5
- Price / sales
- 2.3
- Dividend yield
- 1.39%
- Beta (1 year, vs SPY)
- -0.09
Where the price sits in its year
52-week range
88% of the range
- Below the 52-week high
- -3.8%
- Above the 52-week low
- +39.8%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day average, above its 200-day
- 20-day average
- $233.26+1.7%
- 50-day average
- $237.35-0.1%
- 200-day average
- $209.48+13.2%
Between the conventional 30 and 70 bands.
+2.9%
1 week
-3.2%
1 month
+13.0%
3 months
+36.6%
Year to date
+25.1%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with DGX
DGX on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on DGX.
See the plans →
Every planScreen names like DGX
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on DGX
Put DGX on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on DGX
See whether there is an open premium alert on DGX, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
DGX headlines
- Health Coalition Issues Open Letter to Health Minister to Stop Transfer of Lab Testing by Quest/Lifelabs to U.S.
GlobeNewswire Inc. · Jun 15, 2026
- Quest Diagnostics Declares Quarterly Cash Dividend
Benzinga · May 19, 2026
- Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization
Benzinga · Feb 10, 2026
- Fertility Test Market Report 2025-2033, with Profiles of Quest Diagnostics, Mayo Clinic Laboratories, Ovation Fertility, Illume Fertility, Proov, BioMerieux, Labcorp, CCRM Fertility, and Maven Clinic
GlobeNewswire Inc. · Oct 21, 2025
- North America Autoimmune Disease Diagnostics Market Report 2025-2033 Featuring Bio-Rad, Abbott, Roche, Quest Diagnostics, Thermo Fisher Scientific, BioMerieux, Myriad Genetics, Siemens Healthineers
GlobeNewswire Inc. · Jul 29, 2025
- Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence
Benzinga · Apr 22, 2025
- Quest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer Screening
Benzinga · Apr 2, 2025
- Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
GlobeNewswire Inc. · Dec 19, 2024
SEC Form 4, most recent first
Insider filings
WENTWORTH TIMOTHY C
+135
Director · Grant or award
· Oct 1, 2026
Davis J. E.
−10.0K
CEO and President, Director · Open-market sale
$2.43M · Sep 1, 2026
PREVOZNIK MICHAEL E
−6.2K
SVP & General Counsel · Open-market sale
$1.52M · Aug 28, 2026
PREVOZNIK MICHAEL E
−22.7K
SVP & General Counsel · Option exercise
$2.54M · Aug 28, 2026
PREVOZNIK MICHAEL E
−1.0K
SVP & General Counsel · Gift
· Aug 28, 2026
PREVOZNIK MICHAEL E
−430
SVP & General Counsel · Open-market sale
$105.14K · Aug 28, 2026
PREVOZNIK MICHAEL E
+22.7K
SVP & General Counsel · Option exercise
$2.54M · Aug 28, 2026
PREVOZNIK MICHAEL E
−16.0K
SVP & General Counsel · Open-market sale
$3.89M · Aug 28, 2026
About Quest Diagnostics Inc.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
- Exchange
- NYSE
- Security
- Common stock
- Industry
- Services-Medical Laboratories
- Headquarters
- Secaucus, NJ
- Employees
- 57,000
- Listed since
- Dec 17, 1996
- Website
- questdiagnostics.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.